Infectious-Diseases

Long-term safety and efficacy of tPA and DNase

Long-term safety and efficacy of tPA and DNase

Pleural infection is associated with considerable morbidity and mortality.

Effective removal of the infected pleural fluid and efficient delivery of appropriate antimicrobial therapy are the two principles of treatment.

Researchers at the Institute for Respiratory Health have shown that the novel treatment tPA and DNase when given intrapleurally successfully cures, without needing surgery, 90+% of patients who failed antibiotic treatment and simple drainage.

We are continuing to establish the safety and efficacy of intrapleural tPA/DNase therapy through a comprehensive follow-up program and a multinational patient registry.

To get involved or for more information, contact the Research Leader.

Long-term safety and efficacy of tPA and DNase was last modified: May 12th, 2016 by Sarah Cermak

Research Leaders

Prof Gary Lee

MBChB, PhD, FRACP, FRCP, FCCP

Head of Pleural Medicine Group

gary.lee@health.wa.gov.au
LinkedIn

Prof Gary Lee was last modified: February 24th, 2017 by Sarah Cermak

Long-term safety and efficacy of tPA and DNase was last modified: May 12th, 2016 by Sarah Cermak